An expanded drug screening panel that adds benzodiazepines, barbiturates, and methadone to the standard 5-panel base — giving employers, healthcare organizations, and courts broader prescription drug and sedative coverage in a single urine test.
The 9 panel drug test is an expanded urine drug screening panel that builds directly on the standard 5-panel test. It covers the same five core categories — marijuana (THC), cocaine, opiates, amphetamines, and PCP — and adds four additional substance categories: barbiturates, benzodiazepines, methadone, and a separate methamphetamine screen. The result is broader prescription drug coverage in a single test, without the cost of a full 10-panel screen.
Employers in healthcare, transportation, safety-sensitive roles, and regulated industries choose the 9 panel when they need to detect sedative and prescription drug misuse beyond the standard 5-panel scope. Courts, probation programs, and treatment monitoring authorities also frequently require the 9 panel when broader substance visibility is needed. Every collection at Midwest Identity Services follows certified chain-of-custody procedures with MRO review of all non-negative results.
The 9 panel adds three substance categories that are increasingly relevant in workplace safety and court-ordered testing: benzodiazepines (Xanax, Valium, Klonopin), barbiturates (phenobarbital, secobarbital), and methadone — all of which can cause significant impairment but are missed by a standard 5-panel screen. If your workplace involves safety-sensitive roles, healthcare settings, or prescription drug concerns, the 9 panel offers meaningful additional coverage. Call (816) 442-0295 if you're unsure which panel is right for your situation.
Panels 1–5 are the standard base. Panels 6–9 (highlighted in gold) are the expanded additions that make this test broader than the standard 5-panel screen.
Psychoactive compound in cannabis. THC metabolites are stored in fat cells — the longest detection window of any panel substance.
A powerful stimulant. Detected via its primary metabolite benzoylecgonine. Short detection window — typically clears within 2–4 days.
Screens for codeine, morphine, and heroin metabolite (6-AM). Covers traditional opiates — separate from the synthetic opioids in expanded panels.
Screens for amphetamine and related stimulants. These drugs can cause agitation, paranoia, and dangerous impairment in any workplace setting.
Causes severe hallucinations and dissociation. One of the most dangerous substances for workplace impairment — second longest detection window on this panel.
Benzodiazepines, barbiturates, and methadone are all commonly prescribed medications. A non-negative result does not automatically mean a violation. The MRO will contact you before a final result is issued to verify any legitimate medical explanation — including valid prescriptions. Always disclose all current prescription medications at intake, especially sedatives, anti-anxiety medications, and opioid treatment drugs.
The 9 panel is chosen when the standard 5-panel is not comprehensive enough — typically in industries with prescription drug safety concerns, healthcare environments, legal proceedings, or stricter employer policies.
Hospitals, clinics, and healthcare facilities screen employees with the 9 panel to detect benzodiazepine and barbiturate misuse — substances that may be accessible in clinical environments and can seriously impair patient care performance.
Courts, probation officers, and diversion programs require the 9 panel when they need to monitor a broader range of substances — particularly prescription drug misuse by individuals involved in drug-related legal proceedings.
Construction, manufacturing, security, and other safety-sensitive non-DOT industries use the 9 panel when their risk profile calls for detection of sedatives and benzodiazepines that impair motor skills and reaction time but are missed by a 5-panel.
Employers who have identified prescription drug misuse as a specific concern in their workforce use the 9 panel in their random testing programs to add barbiturate, benzodiazepine, and methadone detection to their standard screening rotation.
Substance abuse treatment programs and monitoring authorities use the 9 panel to verify compliance with treatment agreements — including methadone maintenance programs and sobriety monitoring that must detect benzodiazepines and other sedatives.
Employers who conduct pre-employment drug screening and want broader substance coverage than the standard 5-panel — without moving to a full 10-panel — use the 9 panel as a cost-efficient middle-ground screening option.
Not sure which panel is right for your situation? This comparison shows exactly what each panel adds over the previous one — so you can choose the right coverage level for your needs.
| Substance Screened | 5 Panel | 9 Panel | 10 Panel |
|---|---|---|---|
| Marijuana (THC) | ✓ Included | ✓ Included | ✓ Included |
| Cocaine | ✓ Included | ✓ Included | ✓ Included |
| Opiates (Codeine, Morphine, Heroin) | ✓ Included | ✓ Included | ✓ Included |
| Amphetamines | ✓ Included | ✓ Included | ✓ Included |
| Phencyclidine (PCP) | ✓ Included | ✓ Included | ✓ Included |
| Methamphetamines (dedicated screen) | May vary | ✓ Included | ✓ Included |
| Barbiturates (phenobarbital, secobarbital) | ✗ Not included | ✓ Included | ✓ Included |
| Benzodiazepines (Xanax, Valium, Klonopin) | ✗ Not included | ✓ Included | ✓ Included |
| Methadone | ✗ Not included | ✓ Included | ✓ Included |
| Propoxyphene / Quaaludes (Methaqualone) | ✗ Not included | ✗ Not included | ✓ Included |
For most general employers, the 5 panel is sufficient. The 9 panel is the right step up when benzodiazepine, barbiturate, or methadone detection is specifically needed — common in healthcare, court-ordered, and treatment monitoring situations. The 10 panel adds propoxyphene and methaqualone for the broadest standard coverage. Call (816) 442-0295 and we'll recommend the right panel for your specific needs.
Expanded panel testing requires the same collection discipline as any certified test — proper chain-of-custody, MRO review, and accurate substance identification. We deliver all three on every test.
Every collection follows certified chain-of-custody procedures — tamper-evident seals, temperature verification, and complete documentation. Results are legally defensible for employer review, court submission, and audit scrutiny.
Because benzodiazepines, barbiturates, and methadone are commonly prescribed, MRO review is especially critical on 9-panel tests. The MRO contacts the donor before any non-negative is finalized — protecting both employees and employers from false positives.
Negative results typically within 24–48 hours. Non-negative results with MRO review returned within 1 minute up to 5 days total. Keeping your hiring, court, and compliance timelines on schedule.
5, 9, and 10 panel tests all available at the same location — as well as DOT 5-panel, oral swab, urine alcohol, and breath alcohol testing. One provider for your complete drug and alcohol testing program.
Individual tests and full employer programs — random pool management, pre-employment, and post-accident screening. We also support court-ordered and probation testing programs requiring the 9-panel with proper result reporting.
Not sure whether you need the 9 panel, 10 panel, or DOT test? Call (816) 442-0295 and we'll help you select the right panel for your industry, role, or court requirement before you book — no guesswork.
More questions? Call (816) 442-0295 and we'll answer in two minutes.
All 9 panels screened in a single urine test — certified chain-of-custody collection, MRO-reviewed results, same-day appointments available.
8101 E. Bannister Rd · Kansas City, MO 64134 · Cost: $60–$99 based on services needed
